Bicara Therapeutics Executive Liquidates Position Amid Clinical Progress
Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (NASDAQ: BCAX), executed a series of stock sales totaling approximately $833,129 under a pre-arranged trading plan. The transactions, which followed the exercise of stock options, occurred on July 8 and July 9, 2026, as shares traded near their 52-week high. Concurrently, the biotech firm…